Form 4: 4D Molecular Therapeutics Director Jacob Chacko Acquires Stock Options

Director Jacob Chacko acquired 22,500 stock options in 4D Molecular Therapeutics on May 21, 2024, as part of the company's non-employee director compensation program.

Summary

• On May 21, 2024, Jacob Chacko, a director of 4D Molecular Therapeutics, acquired 22,500 stock options.
• The options were granted automatically under the company's non-employee director compensation program.
• The exercise price of the stock options is $25.15.
• The options vest in three tranches: 1/3 on May 21, 2025, and then in equal monthly installments until fully vested on May 21, 2027, contingent upon continued service.
• The stock options will vest in full upon the consummation of a Change in Control as defined in the 2020 Incentive Award Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard compensation practice that aligns director interests with shareholders, but doesn't contain any groundbreaking news.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing the size and vesting schedule of these options to those of directors at similar-stage gene therapy companies like Rocket Pharmaceuticals or Passage Bio would provide a more detailed benchmark.
• Generally, vesting schedules of three to four years are standard for director stock options.

Stakeholder Impact

• The stock option grant has a minor positive impact on shareholders by aligning director incentives with long-term company performance.

Key Dates